SCHEMA



a. See **LUNGMAP** Section 5.1 for registration information. Participants must be screened on **LUNGMAP** at the time of radiographic or clinical disease progression on osimertinib, in order to capture MET amplification.
b. See **S1900G** Section 5.1. Participants must submit either tissue for biomarker profiling, commercial FoundationOne CDx test results, or tissue or blood (ctDNA) test results from an accepted CLIA laboratory (see **LUNGMAP** Section 5.1 and 18.7 for details). Tissue or blood sample must be obtained after radiographic or clinical disease progression on osimertinib, alone or in combination with other agent(s), as their most recent line of therapy (See Section 5.1.b). Participants with MET amplification results detected outside of the Lung-MAP study, are required to submit documentation as outlined in **LUNGMAP** Section 18.7.
c. See Section 5.0 for the criteria of MET amplification.
d. See Section 7.7 for criteria for removal from protocol treatment.
e. Notification of sub-study assignment will be provided by the SWOG Statistics and Data Management Center (SDMC) (see **LUNGMAP** Section 11.0 for details).
f. See Section 7.9 for follow up period details.